14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CLSN ranks #19695 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Celsion Corporation Stock Forecast NASDAQ:CLSN

$0.39 (-10.07%)

Volume: 847k

Closed: Jan 21, 2022

Hollow Logo Score: -7.104

Celsion Corporation Stock Forecast

$0.39 (-10.07%)

Volume: 847k

Closed: Jan 21, 2022

Score Hollow Logo -7.104

Celsion Corporation Company Profile

997 Lenox Drive

Lawrenceville NJ 08648



Industry: Biotechnology

Sector: Healthcare

Celsion Corporation


Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. Ltd. for ThermoDox; and a commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. for the production of ThermoDox in mainland China, Hong Kong, and Macau. The company was founded in 1982 and is based in Lawrenceville, New Jersey.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE